No. Combining this product with nitrates can cause a dangerous drop in blood pressure. The combination is contraindicated and should be avoided.
The tablet is generally taken about one hour before anticipated intercourse, allowing both sildenafil and dapoxetine to reach effective plasma levels.
Moderate alcohol intake may increase the risk of hypotension and reduce erectile response. Heavy drinking should be avoided, and patients should monitor how they feel.
Seek immediate medical attention. A prolonged erection (priapism) is a medical emergency that may require pharmacologic or surgical intervention.
Rarely, sildenafil can cause sudden loss of vision or changes in colour perception. Any visual disturbance should be reported to a healthcare professional promptly.
The tablet is formulated for whole-tablet ingestion. Splitting or crushing may affect drug release and efficacy and is not recommended.
Both ingredients are not known to impair psychomotor performance at therapeutic doses. However, if you experience dizziness or visual changes, you should refrain from driving.
No. The combination product is not authorised for sale without a prescription and is considered unlicensed in the United Kingdom.
Dapoxetine has a short half-life (≈1.5 hours) and is intended for use on an as-needed basis, unlike longer-acting SSRIs prescribed for chronic mood disorders.
There is no evidence of physiological dependence with intermittent use of dapoxetine or sildenafil. Nonetheless, ongoing therapy should be reviewed regularly by a clinician.
Extra Super P Force is a combination pill that contains two active ingredients: sildenafil and dapoxetine.
The product is formulated as a 100 mg/100 mg tablet. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has not granted marketing authorisation for a fixed-dose combination of these two agents. Consequently, Extra Super P Force is considered an unlicensed or investigational formulation and must be prescribed, if at all, under specialist supervision.
Sildenafil inhibits the enzyme PDE5, which normally breaks down cyclic guanosine monophosphate (cGMP) in the smooth muscle of the penis. By blocking PDE5, sildenafil allows cGMP to accumulate, leading to smooth-muscle relaxation, increased blood flow, and an erection in response to sexual stimulation. Onset of effect typically occurs within 30-60 minutes, with peak plasma concentrations around one hour and a duration of action of up to 4-5 hours.
Dapoxetine selectively blocks the re-uptake of serotonin at the neuronal synapse, modestly increasing serotonergic tone. This effect lengthens the latency time before ejaculation without causing the long-term serotonergic changes seen with chronic SSRI therapy. The drug reaches peak plasma levels within 1-2 hours after oral intake, and its half-life is approximately 1.5 hours, making it suitable for use on an “as-needed” basis.
When combined, the two agents target the two most common sexual performance concerns in men: the ability to achieve a firm erection and the ability to maintain intercourse for a satisfactory duration.
Because the fixed-dose combination does not have a marketing authorisation in the UK, it is not listed as an approved indication by the MHRA. Each component, however, is approved for its respective condition when prescribed separately:
Research has explored the simultaneous use of a PDE5 inhibitor and a short-acting SSRI to address both ED and PE in a single pill. Small-scale randomised trials have reported improvements in erectile rigidity and ejaculation latency when the drugs are co-administered, but larger, multicentre studies are lacking. The combination is not approved by regulatory agencies in the UK or EU.
Disclaimer: Off-label use of any medication requires a thorough risk-benefit assessment by a qualified healthcare professional. Patients should discuss their individual health profile before initiating such therapy.
This article provides educational information about Extra Super P Force and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
